Clinical Trials Management LLC

1. Janssen Research & Development, LLC $3,449,253 77 payments
2. Moderna TX, Inc. $1,473,633 51 payments
3. AbbVie, Inc. $420,322 160 payments
4. Braintree Laboratories, Inc. $394,981 20 payments
5. Ironwood Pharmaceuticals, Inc $371,211 46 payments
6. Incyte Corporation $297,035 498 payments
7. Mylan Inc. $294,620 19 payments
8. Sumitomo Pharma America, Inc. $290,984 70 payments
9. Abbott Laboratories $245,158 10 payments
10. Celgene Corporation $130,905 2 payments

1. A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2 $1,949,241 39 payments
2. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,463,227 45 payments
3. A Randomized, Double-blind, Placebo-controlled, First-in-human Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of 2 Universal Influenza (Uniflu) Vaccine Components, INFLUENZA G1 mHA and Ad26.FLU.003, in Healthy Adults $1,176,910 23 payments
4. A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease $394,981 20 payments
5. A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations of various RSV.preF-based Vaccine Formulations in Adults Aged 60 Years and Older $323,102 15 payments
6. Mr-100A-01-Td-3001-A Phase 3, Multicenter, Open-Label, Single Arm Study of Mr-100A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety $294,620 19 payments
7. C3718-301 $255,262 26 payments
8. A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa $192,708 312 payments
9. A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) $130,905 2 payments
10. Alinity m HR HPV Specimen Collection Study from Women Undergoing Routine Cervical cancer Screening $113,596 4 payments

1. Other $13,167 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.